Beam Therapeutics (BEAM) EBIT Margin (2019 - 2026)
Beam Therapeutics (BEAM) posted quarterly EBIT Margin of 337.81% for Q1 2026, up 125905.0% year-over-year from N/an in Q1 2025, and down 2109.66% quarter-over-quarter from 15.29% in Q4 2025.
Powered by 
Analysis
Beam Therapeutics (BEAM) EBIT Margin (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has reported EBIT Margin for 8 consecutive years, with 337.81% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT Margin rose 125905.0% year-over-year to 337.81%; the TTM figure through Mar 2026 stood at 226.58% (up 45089.0% YoY), while the FY2025 annual figure was 274.57%, up 37968.0% from the prior year.
- EBIT Margin retreated to 337.81% in Q1 2026 per BEAM's latest filing, from 15.29% in the prior quarter.
- Across five years, EBIT Margin topped out at 42.02% in Q4 2023 and bottomed at 1596.87% in Q1 2025.
- Historically, EBIT Margin has averaged 704.39% across 5 years, with a median of 577.9% in 2022.
- Annual changes were most pronounced in 2022 — EBIT Margin surged 333864600 bps — and 2024, when it sank 99663 bps.
- Beam Therapeutics' EBIT Margin stood at 444.1% in 2022, then surged by 109 bps to 42.02% in 2023, then slumped by 892 bps to 332.71% in 2024, then jumped by 95 bps to 15.29% in 2025, then slumped by 2110 bps to 337.81% in 2026.
- Business Quant data shows BEAM's EBIT Margin at 337.81% in Q1 2026, 15.29% in Q4 2025, and 1307.6% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Beam Therapeutics | 3.10 Bn | 3.10 Bn | - | -25,827.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25,827.14% |
| Mar 31, 2026 | -337.81% |
| Dec 31, 2025 | -15.29% |
| Sep 30, 2025 | -1,307.60% |
| Jun 30, 2025 | -1,419.22% |
| Mar 31, 2025 | -1,596.87% |
| Dec 31, 2024 | -332.71% |
| Sep 30, 2024 | -746.40% |
| Jun 30, 2024 | -891.06% |
| Mar 31, 2024 | -1,405.29% |
| Dec 31, 2023 | 42.02% |
| Sep 30, 2023 | -629.72% |
| Jun 30, 2023 | -507.79% |
| Mar 31, 2023 | -408.66% |
| Dec 31, 2022 | -444.10% |
| Sep 30, 2022 | -577.90% |
| Jun 30, 2022 | -492.23% |
| Mar 31, 2022 | -904.00% |
| Dec 31, 2021 | -124.31% |
| Sep 30, 2021 | -9,126.34% |